Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program ExperienceCristina Papayannidis, Giovanni Martinelli, Andrea Ghelli Luserna di Rorà et al.|Blood|2016Cited by 2
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna ExperienceCristina Papayannidis, Giovanni Martinelli, Caterina De Benedittis et al.|Blood|2013Cited by 1
Abstract CT312: Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experienceCristina Papayannidis, Giovanni Martinelli, Caterina De Benedittis et al.|Cancer Research|2014Cited by 0
Abstract 3100: Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experienceGiovanni Martinelli, Cristina Papayannidis, Stefania Paolini et al.|Clinical Research (Excluding Clinical Trials)|2019Cited by 0